Stay updated with the latest stock market news and insights
Weekly insights + SMS alerts
Shares of Agilent Technologies Inc. (A) got a little lift in Monday's premarket trading. The reason? The company is opening its wallet to the tune of about $950 million to buy Biocare Medical, a player in the clinical and research pathology world.
Think of it as Agilent making a nearly billion-dollar bet that the future of its diagnostics business lies in very specific, very tiny antibodies.
Biocare isn't some startup. It's an established name in pathology, particularly in the niche of immunohistochemistry (IHC) and hybridization. In simpler terms, they make the specialized tools and chemical reagents that labs use to stain tissue samples so doctors and researchers can see specific proteins or markers under a microscope. It's a critical step in diagnosing diseases like cancer.
Biocare brings a portfolio of over 300 specialized antibodies to the table, along with a track record of robust research and development. Perhaps most enticing for Agilent is Biocare's financial performance: it's been clocking double-digit revenue and profit growth since 2021.
For Agilent, this isn't just an add-on; it's a strategic muscle-building exercise. Adding Biocare's antibodies, reagents, and instruments will immediately strengthen Agilent's own IHC offerings and broaden its reach into more clinical and research labs. Agilent is banking on Biocare's existing growth in the IHC market and its efficient product innovation engine to turbocharge Agilent's ability to develop and commercialize new in-vitro diagnostic (IVD) antibodies.
The deal is expected to close in Agilent's fourth fiscal quarter of 2026, pending the usual regulatory nods. Once it does, Biocare will become part of Agilent's Life Sciences and Diagnostics Markets Group. Agilent expects the transaction to boost its revenue growth and margins in the first year, improve its mix of non-instrument revenue (which is often more stable and profitable), and become accretive to earnings per share roughly 12 months after closing. The company had about $1.76 billion in cash on hand as of late January, so it has the dry powder for this move.
Now, let's talk about the stock, because that's where things get interesting. Over the past year, Agilent's shares are down about 5.6%. As of the latest check, the stock was trading at $116.41. That's below its 20-day simple moving average of $123.62 and well below its 50-day average of $132.93, which paints a bearish short-term picture.
Some technical indicators hint at a possible turn. The Relative Strength Index (RSI) is sitting at a very oversold 28.41, which often precedes a bounce. However, the MACD indicator remains in bearish territory. It's a mixed bag, suggesting that investors are watching to see if strategic moves like this acquisition can shift the momentum.
The market's initial reaction was positive, with shares up 1.16% to $116.41 in premarket trading Monday.
All eyes will now turn to Agilent's next earnings report, scheduled for May 27, 2026. Investors will be keen to hear management's latest thoughts on integrating Biocare. The current estimates are looking for growth: earnings per share of $1.41 (up from $1.31 a year ago) on revenue of $1.80 billion (up from $1.67 billion). At a P/E ratio of about 25.4x, the market is still valuing Agilent at a premium.
The analyst community is largely staying in Agilent's corner. The consensus rating is a Buy with an average price target of $158.50, implying significant upside from current levels. That said, some have recently trimmed their targets:
The message from the street seems to be: "We still like the long-term story, but we're adjusting for near-term challenges."
For the ETF investors out there, Agilent's moves matter to a few specific funds where it holds notable weight:
Why does this matter? Because if these ETFs see big inflows or outflows from investors, they'll be forced to automatically buy or sell Agilent stock to maintain their target weights. It's a passive market force that can add extra volume and volatility to Agilent's shares based on broader sector trends.
In the end, Agilent is making a classic big-company move: using its strong balance sheet to buy growth and expertise in a strategic area. The $950 million question is whether Biocare's antibodies will be the right chemistry to catalyze a turnaround for Agilent's stock.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
